AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. WVE
  4. [Form 4] Wave Life Sciences Ltd. Insider Trading Activity

[Form 4] Wave Life Sciences Ltd. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

What the filing shows: The Form 4 reports that Tan Aik Na, a director of Wave Life Sciences (WVE), sold 1,127 ordinary shares on August 5, 2025. The sale was made to cover taxes tied to the vesting of restricted share units and was executed pursuant to a 10b5-1 trading plan at a price of $8.75 per share. After the transaction the reporting person beneficially owned 14,988 shares.

Why the filing exists: This is a standard insider disclosure that records an insider sale made for tax withholding related to equity compensation and documents that the sale followed a prearranged plan.

Cosa mostra la comunicazione: Il Modulo 4 indica che Tan Aik Na, amministratore di Wave Life Sciences (WVE), ha venduto 1.127 azioni ordinarie il 5 agosto 2025. La vendita 猫 stata effettuata per coprire le imposte legate alla maturazione di unit脿 azionarie soggette a restrizioni ed 猫 stata eseguita ai sensi di un piano di negoziazione 10b5-1 al prezzo di $8,75 per azione. Dopo l'operazione il soggetto segnalante deteneva beneficiariamente 14.988 azioni.

Perch茅 esiste la comunicazione: Si tratta di una comunicazione interna standard che registra una vendita effettuata per il pagamento delle ritenute fiscali connesse a compensi in azioni e documenta che la cessione 猫 avvenuta secondo un piano predefinito.

Qu茅 muestra la presentaci贸n: El Formulario 4 informa que Tan Aik Na, director de Wave Life Sciences (WVE), vendi贸 1.127 acciones ordinarias el 5 de agosto de 2025. La venta se realiz贸 para cubrir impuestos vinculados al vesting de unidades restringidas de acciones y se ejecut贸 conforme a un plan de negociaci贸n 10b5-1 a un precio de $8,75 por acci贸n. Tras la operaci贸n, la persona informante pose铆a beneficiariamente 14.988 acciones.

Por qu茅 existe la presentaci贸n: Es una divulgaci贸n est谩ndar de un insider que registra una venta destinada a retener impuestos relacionados con la compensaci贸n en acciones y documenta que la venta sigui贸 un plan preestablecido.

鞝滌稖 靹滊鞐� 雮橅儉雮� 雮挫毄: Form 4鞐� 霐半ゴ氅� Wave Life Sciences (WVE) 鞚挫偓鞚� Tan Aik Na电� 2025雲� 8鞗� 5鞚�鞐� 1,127 氤错喌欤�毳� 毵る弰頄堨姷雼堧嫟. 頃措嫻 毵る弰电� 鞝滍暅 欤检嫕 雼渼(restricted share units)鞚� 氩犾姢韺呹臣 甏�霠悳 靹戈笀鞚� 於╇嫻頃橁赴 鞙勴暣 鞚措（鞏挫鞙茧┌, 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 欤茧嫻 $8.75鞚� 臧�瓴╈溂搿� 鞁ろ枆霅橃棃鞀惦媹雼�. 瓯半灅 頉� 氤搓碃鞚胳潃 鞁れ鞝侅溂搿� 14,988欤�毳� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�.

鞝滌稖 靹滊臧� 臁挫灛頃樀鐢 鞚挫湢: 鞚吹鐢 欤检嫕 氤挫儊瓿� 甏�霠悳 靹戈笀 鞗愳矞歆曥垬毳� 鞙勴暣 鞚措（鞏挫 雮措秬鞛� 毵る弰毳� 旮半頃� 響滌 雮措秬鞛� 瓿奠嫓搿滌劀, 毵る弰臧� 靷爠鞐� 鞝曧暣歆� 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃鞚岇潉 氍胳劀頇旐暅 瓴冹瀰雼堧嫟.

Ce que r茅v猫le le d茅p么t : Le Formulaire 4 indique que Tan Aik Na, administrateur de Wave Life Sciences (WVE), a vendu 1 127 actions ordinaires le 5 ao没t 2025. La vente a 茅t茅 r茅alis茅e pour couvrir les imp么ts li茅s au vesting d'unit茅s d'actions restreintes et a 茅t茅 ex茅cut茅e conform茅ment 脿 un plan de n茅gociation 10b5-1 au prix de $8,75 par action. Apr猫s la transaction, la personne d茅clarante d茅tenait b茅n茅ficiairement 14 988 actions.

Pourquoi ce d茅p么t existe : Il s'agit d'une d茅claration d'initi茅 standard qui enregistre une vente effectu茅e pour le paiement des retenues fiscales li茅es 脿 une r茅mun茅ration en actions et qui documente que la vente a suivi un plan pr茅alablement 茅tabli.

Was die Meldung zeigt: Das Formular 4 meldet, dass Tan Aik Na, ein Direktor von Wave Life Sciences (WVE), am 5. August 2025 1.127 Stammaktien verkauft hat. Der Verkauf erfolgte zur Begleichung von Steuern im Zusammenhang mit der Vesting von Restricted Share Units und wurde gem盲脽 einem 10b5-1-Handelsplan zum Preis von $8,75 je Aktie ausgef眉hrt. Nach der Transaktion hielt die meldende Person wirtschaftlich 14.988 Aktien.

Warum die Meldung existiert: Es handelt sich um eine 眉bliche Insider-Meldung, die einen Insider-Verkauf zur Steuerabf眉hrung im Zusammenhang mit Aktienverg眉tung dokumentiert und best盲tigt, dass der Verkauf einem vorab vereinbarten Plan folgte.

Positive
  • Sale executed under a 10b5-1 trading plan, indicating the transaction followed a prearranged compliance mechanism
  • Disclosure lists post-transaction beneficial ownership (14,988 shares), providing transparency
Negative
  • None.

Insights

TL;DR: Routine tax-driven insider sale of 1,127 shares under a 10b5-1 plan; not a material market-moving event.

The Form 4 discloses a single insider sale executed to satisfy taxes from RSU vesting. The sale price is listed at $8.75 and was made under an established 10b5-1 trading plan, which typically reduces timing concerns about opportunistic trading. The remaining beneficial ownership reported is 14,988 shares. From a trading perspective, this type of transaction is generally neutral for investors absent larger or repeated disposals.

TL;DR: Use of a 10b5-1 plan and prompt Form 4 disclosure reflect basic insider compliance and transparency.

The filing identifies the reporting person as a director and documents that the sale was to cover tax obligations from RSU vesting and was executed pursuant to a documented 10b5-1 plan. That combination鈥攑rearranged plan plus timely disclosure鈥攁ligns with good insider-trading governance practices. There is no indication in the filing of policy breaches or unusual timing beyond the RSU vesting event.

Cosa mostra la comunicazione: Il Modulo 4 indica che Tan Aik Na, amministratore di Wave Life Sciences (WVE), ha venduto 1.127 azioni ordinarie il 5 agosto 2025. La vendita 猫 stata effettuata per coprire le imposte legate alla maturazione di unit脿 azionarie soggette a restrizioni ed 猫 stata eseguita ai sensi di un piano di negoziazione 10b5-1 al prezzo di $8,75 per azione. Dopo l'operazione il soggetto segnalante deteneva beneficiariamente 14.988 azioni.

Perch茅 esiste la comunicazione: Si tratta di una comunicazione interna standard che registra una vendita effettuata per il pagamento delle ritenute fiscali connesse a compensi in azioni e documenta che la cessione 猫 avvenuta secondo un piano predefinito.

Qu茅 muestra la presentaci贸n: El Formulario 4 informa que Tan Aik Na, director de Wave Life Sciences (WVE), vendi贸 1.127 acciones ordinarias el 5 de agosto de 2025. La venta se realiz贸 para cubrir impuestos vinculados al vesting de unidades restringidas de acciones y se ejecut贸 conforme a un plan de negociaci贸n 10b5-1 a un precio de $8,75 por acci贸n. Tras la operaci贸n, la persona informante pose铆a beneficiariamente 14.988 acciones.

Por qu茅 existe la presentaci贸n: Es una divulgaci贸n est谩ndar de un insider que registra una venta destinada a retener impuestos relacionados con la compensaci贸n en acciones y documenta que la venta sigui贸 un plan preestablecido.

鞝滌稖 靹滊鞐� 雮橅儉雮� 雮挫毄: Form 4鞐� 霐半ゴ氅� Wave Life Sciences (WVE) 鞚挫偓鞚� Tan Aik Na电� 2025雲� 8鞗� 5鞚�鞐� 1,127 氤错喌欤�毳� 毵る弰頄堨姷雼堧嫟. 頃措嫻 毵る弰电� 鞝滍暅 欤检嫕 雼渼(restricted share units)鞚� 氩犾姢韺呹臣 甏�霠悳 靹戈笀鞚� 於╇嫻頃橁赴 鞙勴暣 鞚措（鞏挫鞙茧┌, 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 欤茧嫻 $8.75鞚� 臧�瓴╈溂搿� 鞁ろ枆霅橃棃鞀惦媹雼�. 瓯半灅 頉� 氤搓碃鞚胳潃 鞁れ鞝侅溂搿� 14,988欤�毳� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�.

鞝滌稖 靹滊臧� 臁挫灛頃樀鐢 鞚挫湢: 鞚吹鐢 欤检嫕 氤挫儊瓿� 甏�霠悳 靹戈笀 鞗愳矞歆曥垬毳� 鞙勴暣 鞚措（鞏挫 雮措秬鞛� 毵る弰毳� 旮半頃� 響滌 雮措秬鞛� 瓿奠嫓搿滌劀, 毵る弰臧� 靷爠鞐� 鞝曧暣歆� 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃鞚岇潉 氍胳劀頇旐暅 瓴冹瀰雼堧嫟.

Ce que r茅v猫le le d茅p么t : Le Formulaire 4 indique que Tan Aik Na, administrateur de Wave Life Sciences (WVE), a vendu 1 127 actions ordinaires le 5 ao没t 2025. La vente a 茅t茅 r茅alis茅e pour couvrir les imp么ts li茅s au vesting d'unit茅s d'actions restreintes et a 茅t茅 ex茅cut茅e conform茅ment 脿 un plan de n茅gociation 10b5-1 au prix de $8,75 par action. Apr猫s la transaction, la personne d茅clarante d茅tenait b茅n茅ficiairement 14 988 actions.

Pourquoi ce d茅p么t existe : Il s'agit d'une d茅claration d'initi茅 standard qui enregistre une vente effectu茅e pour le paiement des retenues fiscales li茅es 脿 une r茅mun茅ration en actions et qui documente que la vente a suivi un plan pr茅alablement 茅tabli.

Was die Meldung zeigt: Das Formular 4 meldet, dass Tan Aik Na, ein Direktor von Wave Life Sciences (WVE), am 5. August 2025 1.127 Stammaktien verkauft hat. Der Verkauf erfolgte zur Begleichung von Steuern im Zusammenhang mit der Vesting von Restricted Share Units und wurde gem盲脽 einem 10b5-1-Handelsplan zum Preis von $8,75 je Aktie ausgef眉hrt. Nach der Transaktion hielt die meldende Person wirtschaftlich 14.988 Aktien.

Warum die Meldung existiert: Es handelt sich um eine 眉bliche Insider-Meldung, die einen Insider-Verkauf zur Steuerabf眉hrung im Zusammenhang mit Aktienverg眉tung dokumentiert und best盲tigt, dass der Verkauf einem vorab vereinbarten Plan folgte.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tan Aik Na
(Last) (First) (Middle)
C/O WAVE LIFE SCIENCES LTD.,
733 CONCORD AVE.
(Street)
CAMBRIDGE MA 02138
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 08/05/2025 S 1,127(1) D $8.75 14,988 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On August 5, 2025, the reporting person sold 1,127 ordinary shares solely to cover taxes associated with the vesting of restricted share units on August 5, 2025.These sales were made pursuant to a 10b5-1 Trading Plan.
/s/ Aik Na Tan 08/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

Who filed the Form 4 for Wave Life Sciences (WVE)?

Tan Aik Na, identified as a director of Wave Life Sciences, is the reporting person on the Form 4.

How many shares did the insider sell and why (WVE)?

The filing states the insider sold 1,127 ordinary shares to cover taxes associated with the vesting of restricted share units.

At what price were the shares sold in the WVE Form 4?

The reported sale price on the form is $8.75 per share.

Were the WVE sales executed under a trading plan?

Yes. The filing states the sales were made pursuant to a 10b5-1 trading plan.

How many shares did the reporting person own after the transaction (WVE)?

After the reported transaction the reporting person beneficially owned 14,988 shares.
Stock WVE logo
Wave Life Scienc

NASDAQ:WVE

WVE Rankings

#3273 Ranked by Market Cap
N/A Ranked by Dividends

WVE Latest News

Aug 6, 2025
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
Jul 30, 2025
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 23, 2025
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
Jun 20, 2025
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007鈥檚 Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
May 29, 2025
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

WVE Latest SEC Filings

Aug 7, 2025
[Form 4] Wave Life Sciences Ltd. Insider Trading Activity
Aug 5, 2025
[8-K] Wave Life Sciences Ltd. Reports Material Event
Jul 30, 2025
[10-Q] Wave Life Sciences Ltd. Quarterly Earnings Report
Jul 30, 2025
[8-K] Wave Life Sciences Ltd. Reports Material Event
Jun 23, 2025
[ARS] Wave Life Sciences Ltd. SEC Filing

WVE Stock Data

1.36B
133.86M
15.89%
82.47%
10.54%
Biotechnology
Pharmaceutical Preparations
Singapore
SINGAPORE